

GENERAL INFORMATION

VENUE

OBA (Openbare Bibliotheek Amsterdam) Amsterdam Public Library Oosterdokskade 143 1011 DL Amsterdam

REGISTRATION

Registration fee:

Industry delegates € 200,-- Physicians/Academics € 100,-- Phd students/Fellows € 50,--

This fee includes lunch, coffee, tea

Registration on-line only: www.epgs.nl The number of seats is limited, first come first serve.

ACCREDITATION

Accreditation has been requested.
All participants will receive a certificate of attendance.

INFORMATION

For further information please contact:

European Postgraduate Gastro-surgical School (EPGS) Meibergdreef 9 1105 AZ Amsterdam

Tel: 020-566 3926/6468 E-mail: epgs@amc.nl



Contemporary use of therapeutic drug monitoring of biologics in chronic diseases: From point of care to personalised medicine Openbare Bibliotheek Amsterdam (OBA) the Amsterdam Public Library December 7, 2018





Amsterdam UMC

Therapeutic drug monitoring of biologics has moved from a concept to implementation in inflammatory diseases. Sufficient target engagement appears to be of paramount importance, whereas the immunogenicity of the monoclonal antibodies is an additional confounding factor that needs to be addressed. Optimal serum concentrations are the main driver for outcome and personalised medicine.

In this second symposium we will discuss how individualised dosing is being applied successfully in rheumatology, dermatology and gastroenterology.

Also, we will discuss the potential of TDM for biologics in oncology.

Sanquin and the Amsterdam UMC jointly organise this symposium where we aim to bring together clinicians and pharmacists/clinical pharmacologists with a special interest in PK-PD of biologics. Together with the participants from pharma this will create a forum to exchange ideas, make new connections and learn. We look forward to welcoming you in the public library in the very heart of Amsterdam, The Netherlands.

The steering committee

Annick de Vries, Theo Rispens, Phyllis Spuls, Ron Mathôt, Gertjan Wolbink en Geert D'Haens.

FACULTY

Dr. Omoniyi Adedokun, Janssen Research & Development, Spring House, USA Drs. Merel L'Ami. Reade. Amsterdam, the Netherlands

Prof. Gijs van den Brink, GSK, London, UK

Prof. Yehuda Chowers, Rambam Hospital, Haifa, Israel

Prof. Ann Gils, University of Leuven, Leuven, Belgium

Prof. Geert D'Haens, Amsterdam UMC, the Netherlands

Dr. Tim Hickling, Pfizer, New York, USA

Prof. Alwin Huitema, UMC Utrecht, the Netherlands

Dr. Peter Irving, Guys and Thomas Hospital, London, UK

Prof. Tore Kvien, University of Oslo, Norway

Prof. Ron Mathôt, Amsterdam UMC, the Netherlands

Dr. Theo Rispens, Sanquin, Amsterdam, the Netherlands

Prof. Catherine Smith, St John's Institute of Dermatology, London, UK

Prof. Phyllis Spuls, Amsterdam UMC, the Netherlands

Drs. Anne Strik, Amsterdam UMC, the Netherlands

Dr. Carolien Versantvoort, EMA, London, UK

Dr. Annick de Vries, Sanquin, Amsterdam, the Netherlands

Dr. Gertjan Wolbink, Sanquin/Reade/ARC, the Netherlands

PROGRAM	INITROPLICTORY LECTURE	44454505	CECCIONI 2 DEEDED LINDEDCTANDING OF THE DIV
09.30-09.55	INTRODUCTORY LECTURE Challenges and cost of biologics: what will the future offer? Gijs van den Brink	14.15-15.25	SESSION 3: DEEPER UNDERSTANDING OF THE PK OF BIOLOGICS Session chairs: Phyllis Spuls, Ron Mathôt
09.55-11.10	SESSION 1: DESIGNING OPTIMAL DOSING SCHEDULES Session chairs: Geert D'Haens, Gertjan Wolbink	14.15-14.40	What can we learn from anti-cancer biologics? Alwin Huitema
09.55-10.20	The clinicians view: why are many dosing schedules	14.40-15.05	Personalized dosing of biologics in dermatology Catherine Smith
	wrong? Peter Irving	15.05-15.25	Induction versus maintenance dosing: an outdated algorithm?
10.20-10.45	The pharmaceutical industry's view Omoniyi Adedokun		Chairs: Geert D'Haens, Gertjan Wolbink Panel: Yehuda Chowers, Peter Irving, Catherine Smith, Tore Kvien
10.45-11.10	The regulator's view: 'How much use is in the label?' Carolien Versantvoort	15.25-15.55	
	COFFEE BREAK	15.55-17.25	SESSION 4: BIOLOGICS AND BIOSIMILARS IN THE ERA OF PERSONALIZED MEDICINE
11.45-13.00	SESSION 2: IMMUNOGENICITY- HOW TO PREVENT, HOW TO HANDLE		Session chairs: Annick de Vries, Peter Irving
11.45-12.10	Session chairs: Ann Gils, Theo Rispens Incidence, risk factors and pathophysiology of	15.55-16.20	Point of care assays: challenges and benefits Ann Gils
11.40 12.10	immunogenicity - not all antibodies are the same Theo Rispens	16.20-16.35	Clinical application of dashboard systems Anne Strik
12.10-12.35	Immunogenicity - the industry's view Tim Hickling	16.35-16.50	Taper to serum concentration; a way to tackle over-exposure Merel L'Ami
12.35-13.00	Anti-drug antibodies: How to handle, how to prevent? Yehuda Chowers	16.50-17.15	Biosimilars: have switch trials become obsolete? Tore Kvien
13.00-14.15	LUNCH	17.15-17.25 17:30	Q&A FAREWELL DRINKS